Frese-Schaper, Manuela; Keil, Andreas; Steiner, Selina; Gugger, Mathias; Körner, Meike; Kocher, Gregor; Schiffer, Lena; Anders, Hans-Joachim; Huynh-Do, Uyen; Schmid, Ralph; Frese, Steffen R. (2014). Low dose irinotecan improves advanced lupus nephritis in mice potentially by changing DNA relaxation and anti–double-stranded DNA binding. Arthritis & rheumatology, 66(8), pp. 2259-2269. Wiley-Blackwell 10.1002/art.38665
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
art38665.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (205kB) | Request a copy |
|
|
Text
Keil et al 2014 Low-dose irinotecan.pdf - Accepted Version Available under License Publisher holds Copyright. Download (1MB) | Preview |
Objective Albeit clear advances in the treatment of SLE, many patients still present with refractory lupus nephritis requiring new treatment strategies for this disease. Here we determined whether reduced doses of the topoisomerase I inhibitor irinotecan, which is known as chemotherapeutic agent, were able to suppress SLE in NZB/W F1 mice. We further evaluated the potential mechanism how irinotecan influenced the course of SLE. Methods NZB/W F1 mice were treated with low dose irinotecan either from week 24 of age or from established glomerulonephritis defined by a proteinuria ≥grade 3+. Binding of anti-dsDNA antibodies was measured by ELISA; and DNA relaxation was visualized by gel electrophoresis. Results Significantly reduced irinotecan dosages improved lupus nephritis and prolonged survival in NZB/W F1 mice. The lowest dose successfully used for the treatment of established murine lupus nephritis was more than 50 times lower than the dose usually applied for chemotherapy in humans. As a mechanism, low dose irinotecan reduced B cell activity; however, the levels of B cell activity in irinotecan-treated mice were similar to those in Balb/c mice of the same age suggesting that irinotecan did not induce a clear immunosuppression. In addition, incubation of double-stranded (ds) DNA with topoisomerase I increased binding of murine and human anti-dsDNA antibodies showing for the first time that relaxed DNA is more susceptible to anti-dsDNA antibody binding. This effect was reversed by addition of the topoisomerase I inhibitor camptothecin. Conclusion Our results propose topoisomerase I inhibitors as a novel and targeted therapy for SLE. © 2014 American College of Rheumatology.
Actions (login required)
 |
Edit item |